For instance, non-small cell lung cancer (NSCLC) harboring EGFR mutations or ALK translocations and melanomas with BRAF mutations have been shown to be highly sensitive to the corresponding targeted kinase inhibition [1–3]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.